fMRI predictors of treatment outcome in pediatric anxiety disorders by McClure, Erin et al.
Georgia State University
ScholarWorks @ Georgia State University
Psychology Faculty Publications Department of Psychology
2007
f MRI predictors of treatment outcome in pediatric
anxiety disorders
Erin McClure
Georgia State, etone@gsu.edu
Abby Adler
National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services
Christopher Monk
University of Michigan - Ann Arbor
Jennifer Cameron
National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services
Samantha Smith
National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services
See next page for additional authors
Follow this and additional works at: https://scholarworks.gsu.edu/psych_facpub
Part of the Psychology Commons
This Article is brought to you for free and open access by the Department of Psychology at ScholarWorks @ Georgia State University. It has been
accepted for inclusion in Psychology Faculty Publications by an authorized administrator of ScholarWorks @ Georgia State University. For more
information, please contact scholarworks@gsu.edu.
Recommended Citation
McClure, Erin; Adler, Abby; Monk, Christopher; Cameron, Jennifer; Smith, Samantha; Nelson, Eric E.; Leibenluft, Ellen; Ernst,
Monique; and Pine, Daniel, "fMRI predictors of treatment outcome in pediatric anxiety disorders" (2007). Psychology Faculty
Publications. 122.
https://scholarworks.gsu.edu/psych_facpub/122
Authors
Erin McClure, Abby Adler, Christopher Monk, Jennifer Cameron, Samantha Smith, Eric E. Nelson, Ellen
Leibenluft, Monique Ernst, and Daniel Pine
This article is available at ScholarWorks @ Georgia State University: https://scholarworks.gsu.edu/psych_facpub/122
fMRI PREDICTORS              1              
 
 
 
 
RUNNING HEAD: FMRI PREDICTORS 
 
 
 
 
fMRI predictors of treatment outcome in pediatric anxiety disorders 
 
 
 
 
Erin B. McClure*1; Abby Adler2; Christopher S. Monk3; Jennifer Cameron4; Samantha Smith4;  
Eric E. Nelson2; Ellen Leibenluft5; Monique Ernst2; Daniel S. Pine2 
 
1Department of Psychology, Georgia State University 
2Emotional Development and Affective Neuroscience Branch, Mood and Anxiety Disorders 
Program, National Institute of Mental Health, National Institutes of Health, Department of 
Health and Human Services 
3Department of Psychology and the Center for Human Growth and Development, University of 
Michigan at Ann Arbor 
4Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes 
of Health, Department of Health and Human Services 
5Unit on Affective Disorders, Pediatrics and Developmental Neuropsychiatry Branch, Mood and 
Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, 
Department of Health and Human Services 
 
*Correspondence to: Erin B. McClure; Department of Psychology; Georgia State University; 
P.O. Box 5010, Atlanta, Georgia, 30302-5010; emcclure@gsu.edu.
fMRI PREDICTORS              1              
 
Abstract 
 A growing number of studies have found evidence that anxiety and depressive disorders 
are associated with atypical amygdala hyperactivation, which decreases with effective treatment. 
Interest has emerged in this phenomenon as a possible biological marker for individuals who are 
likely to benefit from tailored treatment approaches. The present study was designed to examine 
relationships between pre-treatment amygdala activity and treatment response in a sample of 
anxious children and adolescents. Participants, who were diagnosed predominantly with 
Generalized Anxiety Disorder (GAD), underwent functional magnetic resonance imaging (fMRI) 
scanning prior to treatment with fluoxetine or cognitive behavioral therapy (CBT). Results 
indicated significant negative associations between degree of left amygdala activation and 
measures of post-treatment symptom improvement in the group as a whole. Taken together with 
research on associations between adult amygdala activation and treatment response, these 
findings suggest that patients whose pre-treatment amygdala activity is the strongest may be 
particularly likely to respond well to such widely used treatments as selective serotonin reuptake 
inhibitor (SSRI) medications and CBT. 
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Recent years have seen an intense research focus on the amygdala as a potential neural 
substrate of various mood and anxiety disorders. This attention stems from convergent findings 
in the neuroscience literature that the amygdala plays a prominent role in processing emotional 
cues (1). Given the atypical emotional responses of individuals with anxious or depressive 
disorders, researchers have hypothesized that anomalies in neural structures involved in 
perceiving, evaluating, and responding to emotional stimuli may characterize these patient 
groups. Consistent with this hypothesis, accumulating evidence associates aberrant amygdala 
function, typically enhanced activity, with anxiety disorders and major depressive disorder 
(MDD) (2-6).   
In adults, amplified amygdala responses to salient emotional cues have been 
demonstrated in patients with social anxiety disorder (3, 7), post-traumatic stress disorder 
(PTSD) (2, 4), and specific phobias (5), as well as MDD (8-10). A smaller body of research in 
adolescents with mood and anxiety disorders has generated similar evidence of atypical 
amygdala responsiveness (6, 11-13), mostly hyperactivity. One study, however, found 
hypoactivity in a small sample of depressed females (6). Limited research has focused on youth 
with specific anxiety disorders; however, in a larger study comparing amygdala responses 
between patients with GAD and healthy peers (14), we found compelling evidence of a 
distinctive pattern of elevated amygdala activity in youth with GAD when their attention was 
constrained to their own internal emotional states. 
Effective treatments appear to alter these atypical patterns, in that they produce 
significant decreases in amygdala activity in anxious and MDD adults, as do pharmacological 
challenges in healthy adults (3, 8, 9, 15-18).  Studies of adults have found decreases in amygdala 
activation to relate to successful treatment of MDD (8, 9) and social phobia (3, 16, 17). Whereas 
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some studies have found decreased activation to be limited to the left amygdala (8), others have 
obtained evidence of bilateral decreases in activation in this region (9, 16).  Whether comparable 
treatment-related changes are evident in youth remains unclear due to a dearth of studies 
examining neural correlates of therapeutic response in children and adolescents.   
These findings have spurred interest in pre-treatment amygdala hyperactivation as a 
potential marker of symptomatology likely to diminish with treatment.  Such work is important 
in that it might ultimately allow measures of amygdala function to be used as predictors of 
treatment.  One recent study of adult MDD, for example, found significant associations between 
magnitude of treatment response and pre-treatment amygdala activation during the processing of 
emotional information (10).  Specifically, enhanced pre-treatment reactivity in the right 
amygdala predicted a better response to cognitive behavioral psychotherapy (CBT).  It remains 
unclear whether a similar association is apparent in individuals with anxiety disorders or in 
individual receiving psychotherapeutic treatments besides CBT.   
The overwhelming majority of research on amygdala activity and psychopathology has 
been performed in adults.  In particular, no study in youth has examined associations between 
amygdala activity and response to treatment.  Such work is important in mood and anxiety 
disorders, given emerging data on amygdala function in these conditions (6, 12), coupled with 
questions surrounding therapeutics.  For instance, it is unclear why youth show a different 
pattern of responses to antidepressant medications, including a possible increased risk of suicidal 
ideation, than adults (19).  Similar questions have emerged about CBT, as one recent study in 
adolescent MDD found that CBT alone showed no advantage over pill-placebo, but CBT was 
helpful when combined with fluoxetine (20).   
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Heterogeneous treatment response patterns have emerged in pediatric research.  Some 
patients exhibit robust treatment responses, whereas others respond more poorly, perhaps 
reflecting pathophysiological heterogeneity (21-23).  However, it is difficult to distinguish 
between responders and non-responders prior to treatment; in particular, clinical measures have 
fared poorly as strong, consistent predictors of treatment response.  If pre-treatment measures of 
amygdala activity could be shown to predict patient outcomes, such measures might provide 
novel insights into mechanisms underlying heterogeneous treatment responses.   
This study examines associations between pre-treatment amygdala activation and 
treatment response in pediatric anxiety disorders, in a sample predominantly diagnosed with 
Generalized Anxiety Disorder (GAD). We tested the hypothesis that enhanced pre-treatment 
amygdala activity predicts a better treatment response. This hypothesis is based on the premise 
that amygdala activation is one substrate on which CBT and selective serotonin reuptake 
inhibitor (SSRI) medications act. Thus, treatment response is predicted to relate significantly to 
degree of pre-treatment amygdala activation; individuals who show less activity are presumed to 
suffer from anxious symptoms stemming from a different neural basis than those with higher 
levels of activation.  This hypothesis receives support from work in adults, where pre-treatment 
amygdala hyperactivation predicts response to CBT (10).     
 
Method 
Subjects. Fifteen children and adolescents with DSM-IV anxiety disorder diagnoses (7 female; 
11.7± 2.0 years) were recruited from the local community to participate in a study at the National 
Institute of Mental Health (NIMH). Post-treatment clinical data were not available for 3 of these 
adolescents, who were excluded from analyses. Demographic data for the 12 participants with 
complete data, as well as for those who were excluded, are presented in Table 1.  During a 
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screening visit, each participant completed the Wechsler Abbreviated Scales of Intelligence 
(WASI) (24) and a battery of behavioral tasks, all administered by trained research technicians. 
Additionally, either a psychologist or psychiatrist assessed each participant with the Schedule for 
Affective Disorders and Schizophrenia for School-Age Children (K-SADS) (25). The majority 
(n=9) received current diagnoses of GAD; three participants received primary diagnoses of social 
phobia.  For three subjects, while symptoms of GAD were present, they were less severe or 
impairing than symptoms of social phobia.   
Current severity was rated by trained clinicians (psychologists and psychiatrists) using 
the Clinical Global Impressions Severity (CGI-S) and Improvement (CGI-I) scales (26). The 
CGI-S generates severity ratings along a seven-point scale, where 1 indicates normal functioning 
and 7 indicates extreme illness. The CGI-I, which scores participants along an eight-point scale 
from 1 (completely recovered) to 8 (much worse), was also used to assess participants’ 
improvement during treatment. Ratings were completed at baseline, four weeks, and at the end of 
treatment.  All patients had been free of psychotropic medication for at least one year. 
 After three weeks of screening and supportive therapy, participants were acclimated to 
the MRI environment in a mock scanner and then underwent the pre-treatment fMRI scan. They 
were then enrolled in eight weeks of treatment consisting of either fluoxetine (n=5) or CBT 
(n=7).  Choice of treatments was based on preference of the families.  For patients in the 
fluoxetine condition, medication was started at 5 mg and increased every two weeks as 
recommended by a clinician to a maximum of 40 mg by week four. Dosage increases were based 
on both symptoms and side effects, using procedures from the RUPP Anxiety Study.  The 
remaining participants met with a licensed clinical psychologist for weekly CBT.  Each session 
lasted approximately 60-90 minutes and focused on exposure and skills training, using methods 
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outlined in the Social Effectiveness Therapy for Children (SET-C) manual developed by Beidel 
and colleagues (27) and other manualized treatments (28).  Participants underwent post-treatment 
MRI scanning in the week after treatment ended. The study was approved by the NIMH 
Institutional Review Board and all participants/parents provided written informed assent/consent.  
fMRI Task. The face-attention paradigm, described in detail in prior publications (29, 
30), requires participants to view a randomly ordered series of 32 standardized grayscale 
evocative faces (eight stimuli representing each of four emotions: afraid, happy, neutral, angry) 
drawn from three widely used stimulus sets (31-33). Each face is viewed repeatedly, once during 
each of four epochs that alternate in randomized order.  During three epochs, participants adopt 
different attention states, each of which directs them to make a specified rating (“How afraid are 
you?”, “How hostile is the face?”, “How wide is the nose?”) of each face stimulus.  During the 
fourth epoch, subjects passively view stimuli. Stimuli are presented through Avotec Silent Vision 
Glasses (Stuart, FL).  Rating and response time for each trial are recorded using a 5-key MRI-
compatible glove device (MRI Devices, Waukesha, WI).  
The task uses a rapid-event-related-mixed/hybrid design, in which 32 4000 msec “blank” 
trials or “null-events” are interspersed among stimulus trials. This design ensures that each 
stimulus appears at a randomly varying point within the hemodynamic response function (HRF).    
The task is presented in one 160-trial run (14-minutes, 42-seconds). During this run, the 
four epochs/rating blocks (each of which comprises 10 randomly-ordered 4000 msec events—
eight face and 2 “null event” trials—preceded by a 3000 msec instruction screen) alternate. 
Participants rate the stimuli during the 4000 ms period when faces are displayed.  Each event is 
followed by an inter-trial interval varying in duration from 750-1250 ms.  
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Subjects participating in this study had also participated in a larger study comparing 
amygdala responses between patients with GAD and matched healthy adolescents (14).  This 
larger study showed that patients with GAD exhibited a pattern of amygdala hyperactivity that 
was most pronounced during the contrast of fearful-face-viewing events with happy-face-
viewing events, when both are viewed in the “How afraid?” attention state.  All subjects in the 
current study had participated in this previous study.  Given that this contrast most robustly and 
precisely differentiated anxiety patients from healthy youth in the prior study (14), the analyses 
for the current report focus only on the degree to which amygdala activation within this contrast 
predicts treatment response.   
Procedures. We gathered functional MRI data on a 3-Tesla GE-scanner using echo-
planar single shot gradient echo T2* imaging (axial plane, 23 slices) after sagittal localization 
and manual shimming (64x64 matrix; TR=2000 ms, TE=40 ms, FOV=240 mm; 3.75 x 3.75 x 5 
mm voxels).  We acquired images in 23 contiguous slices parallel to the AC-PC line. We also 
acquired high-resolution T1 weighted anatomical images to aid with spatial normalization (180 
1-mm axial slices, FOV=256, NEX=1, TR=11.4 ms, TE=4.4 ms, matrix=256x256, TI=300 ms, 
bandwidth=130 Hz/pixel, 33 kHz/256 pixels). 
 fMRI pre-processing. For all participants, movement was < 1 voxel in any plane.  We 
conducted analyses with SPM software (SPM99, Wellcome Department of Neurology) and 
Matlab 5.3 routines. We corrected functional data for slice timing and motion, co-registered them 
to the anatomical data, spatially normalized and re-sliced them.  After pre-processing, we 
evaluated the quality of the normalization procedure via visual inspection of fMRI images. 
Data Analysis: We estimated event-related response amplitudes at the individual 
participant level for each event type (angry, fearful, happy, neutral faces) in each attention state 
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(how afraid, how wide is the nose, how hostile is the face, passive viewing) using the General 
Linear Model (GLM).  The waveform for each event-related response was a rectangular pulse 
(4s duration) convolved with the HRF specified by SPM99.  For analysis of amygdala activation, 
we calculated separate mean contrast values for the entire volume of each participant’s left 
amygdala and right amygdala using unsmoothed data for the fear vs. happy comparison within 
the “How afraid are you?” attention state. This approach circumvented potential problems with 
partial volume effects that can arise when smoothed data are used, as is required for the standard 
small volume correction approach. Such problems are particularly likely to affect small neural 
structures such as the amygdala, which are vulnerable to susceptibility artifacts. The amygdala 
ROIs were drawn from the MNI template and individual subject brains were normalized to the 
MNI brain (34).   
Statistical Tests:  We used Bonferroni corrected Spearman correlations to examine associations 
between pre-treatment relative amygdala activation in the afraid-fear vs. afraid-happy contrast 
and both post-treatment CGI-I scores and CGI-S change scores between pre- and post-treatment 
assessments. Additionally, we conducted linear regression analyses, with CGI-S post-treatment 
score as the outcome variable, amygdala activation as the predictor variable, and CGI-S pre-
treatment score as a covariate to control for differences in pre-treatment symptom severity. 
Results 
 Neither amygdala activation nor CGI-S or CGI-I scores were significantly associated 
with age or sex (all p’s > .025); therefore, demographic variables were not included as covariates 
in further analyses. 
Overall, participants showed significant improvement with treatment; paired samples t-
tests showed significant differences between pre-treatment and post-treatment CGI-S scores, 
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t(11)=5.348, p < .001 (see Figure 1), with a mean CGI-I score of 2.33 (SD=1.23).  Pre-treatment 
CGI-S score was not significantly associated with activation during the afraid-fear vs. afraid-
happy contrast in either the left amygdala, r=.17, p=.59, or the right amygdala, r=.04, p=.90.  
Spearman correlations, however, yielded evidence of significant associations between pre-
treatment amygdala activation and measures of both post-treatment symptom severity and 
clinical improvement. Specifically, we found a significant negative association between 
activation in the left amygdala in the afraid-fear vs. afraid-happy contrast and post-treatment 
CGI-I score, ρ = -.65, p<.02. A non-significant trend for association was evident between left 
amygdala activation in this contrast and CGI-S score,  ρ = -.61, p<.04 (see Figures 2a and 2b). 
Associations were not statistically significant between activation in the right amygdala in the 
afraid-fear vs. afraid-happy contrast and either post-treatment CGI-S score, Spearman r=-.27, 
p=.41, or CGI-I score, ρ = -.10, p=.75. 
Regression analyses with pre-treatment CGI-S score included as a covariate yielded 
comparable findings. Left amygdala activation in the afraid-fear vs. afraid-happy contrast 
significantly predicted post-treatment CGI-S scores, Beta = -,61, R2 Change = .36, F Change 
(1,9)= 5.09, p=.05. Right amygdala activation in the same contrast, however, did not 
significantly predict CGI-S score at post-treatment, Beta = -,04, R2 Change = .001, F Change 
(1,9)= .01, p=.91. 
Discussion 
Results of the present study indicate that better responses to medication or CBT treatment 
were associated with greater pre-treatment activation in the left amygdala during pediatric 
anxiety disorder patients’ attention to their own internal, emotional responses to fearful faces 
compared to happy faces. Associations were strongest when improvement between screening and 
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Week 8 of treatment served as the measure of treatment response; however, analyses focused on 
post-treatment symptom severity also approached significance. In contrast, pre-treatment 
symptom severity was not significantly associated with activation in either the right or left 
amygdala. These findings suggest that fluoxetine or CBT treatment may be most effective for 
youth who show a pattern of amplified amygdala reactivity while attending to their internal 
responses to emotionally salient cues. 
The absence of significant associations between pre-treatment symptom severity and 
amygdala activation is consistent with some prior research; however, findings in this area are 
highly inconsistent.  The few adult studies that have examined correlations between amygdala 
activity and anxiety severity have yielded mixed findings, with some showing evidence of 
significant positive relationships (35) and others demonstrating non-significant associations 
between the two (36). Two recent studies found amygdala activation to relate to one, but not a 
second, measure of anxious symptoms Similar inconsistency is evident in studies of youth; 
whereas some recent research in a clinical adolescent sample yielded no evidence of a 
relationship between symptom severity and amygdala activation (37), findings in another study 
focused on a healthy sample point to a linear association (11). Patterns of correlation appear to 
vary depending on a number of factors, including the sample under study and the task used to 
elicit amygdala activation; clearly further study  that carefully controls such factors is needed to 
elucidate the relationship between pre-treatment symptomatology and amygdala activation.  
The present findings are necessarily preliminary, given the limitations of the current 
study.  In particular, our sample was small and heterogeneous with regard to both age (8-16 
years) and diagnosis, which increases the risk of Type II error by reducing statistical power. 
However, in the present study we obtained positive findings, which suggests that power was 
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adequate, despite the small sample size.  Replication in a larger, homogeneous group of pediatric 
patients is clearly warranted; the present data could serve as a useful basis for hypothesis 
generation in such research.      
It is of note that post hoc analyses revealed no significant associations between age and 
either amygdala activation or treatment response, which suggests that effects may be similar 
across developmental periods during youth. Power to detect such diffs is limited in small sample 
Additionally, the number of participants in each treatment condition was too small to permit 
comparison of patterns of association across the two. Future studies should include an adequate 
sample size to permit separate examination of effects for different treatment modalities or 
placebo control; this will be critical to determine whether amygdala reactivity is more strongly 
associated with response to any particular therapeutic approach or if it relates instead to a natural 
course of remission, regardless of treatment. Furthermore, we did not include post-treatment 
MRI scan data, which would be necessary to show that amygdala activation decreased in 
treatment responders.  Such data would address a related but conceptually different question than 
the one addressed here, concerning the relationship between pre-treatment fMRI response and 
treatment prediction.  The current study is designed to consider the possible utility of fMRI 
measures as predictors of treatment success.  Finally, because we did not include a placebo-
control group, it is unclear whether amygdala activation is associated with treatment response per 
se or with symptom improvement, which could occur in the absence of treatment. 
Despite the preliminary nature of the present findings, they are broadly consistent with 
the results of comparable research in adults. In particular, one very recent study provided 
compelling evidence that pre-treatment amygdala reactivity may effectively predict adult 
response to CBT for MDD (10). In this study, Siegle and colleagues found that right amygdala 
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reactivity to negative verbal stimuli prior to treatment was significantly associated with strength 
of response to treatment with CBT in MDD patients. The present study obtained similar findings 
in a sample of anxious youth diagnosed predominantly with GAD, such that pre-treatment left 
amygdala activation to negative visual cues, particularly during attention to one’s own emotional 
response to those cues, related significantly to magnitude of improvement across the treatment 
period.  
These two studies differ in several notable ways. First, the patients in the present study 
were undergoing either medication or cognitive behavioral treatment for anxiety disorders, 
predominantly GAD; those in the Siegle et al. study were exclusively undergoing CBT for MDD. 
Second, whereas the adult study required participants to attend to negative verbal stimuli during 
fMRI scans, the present study directed participants’ attention to their internal responses to 
emotional faces. These key differences may contribute to the disparity between studies in 
laterality of amygdala responses that predicted treatment outcome. In particular, a growing 
number of studies indicates that attentional factors exert considerable influence over patterns of 
amygdala activation add katie (14, 30, 38, 39). Future research using comparable paradigms in 
both adult and child patient samples will be useful for clarifying whether the differences in 
laterality of activation associated with outcome reflect methodological inconsistencies between 
studies, differences in diagnostic status of participating patients, or developmental differences in 
the neural substrates of varied psychopathologies.  
Despite their differences, if the present study and Siegle and colleagues’ groundbreaking 
work are taken together, they suggest that amygdala hyperactivity may be a pathological feature 
associated with an array of mood and anxiety disorders. Further, they raise the possibility that 
such hyperactivity could serve as one means by which to identify subgroups of patients who are 
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likely to respond well to standard treatments. Identification of such a biological marker of 
treatment response among pediatric patients would advance the field dramatically. As recent 
reviews have concluded, randomized controlled trials indicate that current treatments are 
effective for only a subset of youth with anxiety and mood disorders (40, 41). Although 
symptom severity and the presence of comorbid disorders sometimes predict poorer outcomes 
(23), this is not always the case. Biological characteristics offer a possible alternative means of 
identifying likely responders; research indicates, for instance, that tendencies to preferentially 
process dichotic auditory stimuli using the left hemisphere may relate to better treatment 
response among adults (42-44). The present findings, along with those of Siegle and colleagues 
(10), suggest that amygdala hyperactivation could serve a similar function.  
It is important to note, however, that even if further research confirms that amygdala 
hyperactivation effectively indexes probability of a positive response to some treatments for 
anxiety and mood disorders, it will likely relate less clearly to responses to others. This 
likelihood is particularly strong, given that pediatric internalizing disorders are likely 
heterogeneous, with different substrates underlying different types of dysfunction (41). Thus, 
amygdala dysfunction may only characterize one subset of youth with disorders that can respond 
to medication or CBT. For other youth, it will be necessary to identify both alternative treatments 
and markers associated with efficacy and effectiveness of those treatments. Nonetheless, 
although research on biological markers of potential treatment response is in its early stages, it 
holds promise for dramatically improving the precision and power of both well-tested and novel 
therapeutic approaches to pediatric anxiety and mood disorders. 
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Figures 
Figure 1. Participants showed a significant change in Clinical Global Impressions (CGI) scale 
scores between pre- and post-treatment assessments. 
Figure 2. Pre-treatment left amygdala activation was significantly and negatively associated with 
both post-treatment Clinical Global Impressions (CGI) symptom severity scores and CGI-
Improvement scores.
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Table 1. 
 
  Participants with 
Complete Data  
Participants missing Post-
Treatment Data 
 N = 12 N = 3 
 
Gender, n (%) 
  
Female 6 (50) 1 (33.3) 
Male 6 (50) 2 (66.6) 
Age, mean (SD) 11.8 (1.8) 11.3 (3.1) 
Age Range 10.0-16.0 8.0-14.0 
IQ, mean (SD) 113.9 (14.9) 107.3 (15.1) 
Treatment, n (%)   
Cognitive Behavioral Therapy 7 (58.3) 2 (66.6) 
Medication 5 (41.7) 1 (33.3) 
CGI severity, mean (SD)   
Baseline 4.3 (0.87) 4.0 (0.82) 
Week 8 2.1 (1.0) 2.0 (0.82) 
Pre-Treatment Diagnoses (Current 
Ongoing) 
  
Generalized Anxiety Disorder 9 (75%) 3 (100%) 
Separation Anxiety Disorder 5 (42%) -- 
Social Phobia 6 (50%) -- 
Specific Phobia 3 (25%) -- 
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Oppositional Defiant Disorder 2 (17%) 1 (33%) 
Dysthymia 1 (8%) -- 
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Figure 1 
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Figure 2 
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